nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP3A7—Sorafenib—liver cancer	0.071	0.123	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.071	0.123	CbGbCtD
Cyclophosphamide—CYP2B6—Sorafenib—liver cancer	0.0676	0.118	CbGbCtD
Cyclophosphamide—CYP3A5—Sorafenib—liver cancer	0.0533	0.0926	CbGbCtD
Cyclophosphamide—CYP2C8—Sorafenib—liver cancer	0.0512	0.089	CbGbCtD
Cyclophosphamide—CYP2C19—Sorafenib—liver cancer	0.043	0.0747	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—liver cancer	0.041	0.0713	CbGbCtD
Cyclophosphamide—CYP2C9—Sorafenib—liver cancer	0.0357	0.0621	CbGbCtD
Cyclophosphamide—ABCB1—Sorafenib—liver cancer	0.0347	0.0603	CbGbCtD
Cyclophosphamide—CYP2D6—Sorafenib—liver cancer	0.0327	0.0568	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—liver cancer	0.021	0.0366	CbGbCtD
Cyclophosphamide—CYP3A4—Sorafenib—liver cancer	0.0208	0.0361	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—liver cancer	0.0198	0.0344	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—liver cancer	0.0126	0.0219	CbGbCtD
Cyclophosphamide—Anaemia—Sorafenib—liver cancer	0.000464	0.00154	CcSEcCtD
Cyclophosphamide—Lacrimation increased—Epirubicin—liver cancer	0.00046	0.00153	CcSEcCtD
Cyclophosphamide—Neoplasm malignant—Doxorubicin—liver cancer	0.00046	0.00153	CcSEcCtD
Cyclophosphamide—Hyperuricaemia—Epirubicin—liver cancer	0.000457	0.00152	CcSEcCtD
Cyclophosphamide—Extravasation—Doxorubicin—liver cancer	0.00045	0.0015	CcSEcCtD
Cyclophosphamide—Leukopenia—Sorafenib—liver cancer	0.000449	0.0015	CcSEcCtD
Cyclophosphamide—Blood bilirubin increased—Epirubicin—liver cancer	0.000448	0.00149	CcSEcCtD
Cyclophosphamide—Ulcer—Epirubicin—liver cancer	0.000448	0.00149	CcSEcCtD
Cyclophosphamide—Amenorrhoea—Doxorubicin—liver cancer	0.000447	0.00149	CcSEcCtD
Cyclophosphamide—Cough—Sorafenib—liver cancer	0.000438	0.00146	CcSEcCtD
Cyclophosphamide—Inflammation—Epirubicin—liver cancer	0.000437	0.00146	CcSEcCtD
Cyclophosphamide—Viral infection—Doxorubicin—liver cancer	0.000434	0.00145	CcSEcCtD
Cyclophosphamide—Hypertension—Sorafenib—liver cancer	0.000433	0.00144	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Epirubicin—liver cancer	0.000432	0.00144	CcSEcCtD
Cyclophosphamide—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000432	0.00144	CcSEcCtD
Cyclophosphamide—Myalgia—Sorafenib—liver cancer	0.000427	0.00142	CcSEcCtD
Cyclophosphamide—Arthralgia—Sorafenib—liver cancer	0.000427	0.00142	CcSEcCtD
Cyclophosphamide—Lacrimation increased—Doxorubicin—liver cancer	0.000426	0.00142	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Epirubicin—liver cancer	0.000424	0.00141	CcSEcCtD
Cyclophosphamide—Ventricular tachycardia—Epirubicin—liver cancer	0.000424	0.00141	CcSEcCtD
Cyclophosphamide—Hyperuricaemia—Doxorubicin—liver cancer	0.000423	0.00141	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Epirubicin—liver cancer	0.000417	0.00139	CcSEcCtD
Cyclophosphamide—Blood bilirubin increased—Doxorubicin—liver cancer	0.000415	0.00138	CcSEcCtD
Cyclophosphamide—Ulcer—Doxorubicin—liver cancer	0.000415	0.00138	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Epirubicin—liver cancer	0.000414	0.00138	CcSEcCtD
Cyclophosphamide—Influenza like illness—Epirubicin—liver cancer	0.000412	0.00137	CcSEcCtD
Cyclophosphamide—Cystitis—Epirubicin—liver cancer	0.00041	0.00136	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Sorafenib—liver cancer	0.000409	0.00136	CcSEcCtD
Cyclophosphamide—Colitis—Epirubicin—liver cancer	0.000407	0.00136	CcSEcCtD
Cyclophosphamide—Infection—Sorafenib—liver cancer	0.000407	0.00136	CcSEcCtD
Cyclophosphamide—Inflammation—Doxorubicin—liver cancer	0.000405	0.00135	CcSEcCtD
Cyclophosphamide—Shock—Sorafenib—liver cancer	0.000403	0.00134	CcSEcCtD
Cyclophosphamide—Fluid retention—Epirubicin—liver cancer	0.000403	0.00134	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Sorafenib—liver cancer	0.000401	0.00134	CcSEcCtD
Cyclophosphamide—Blood uric acid increased—Doxorubicin—liver cancer	0.0004	0.00133	CcSEcCtD
Cyclophosphamide—Pulmonary embolism—Doxorubicin—liver cancer	0.000392	0.00131	CcSEcCtD
Cyclophosphamide—Ventricular tachycardia—Doxorubicin—liver cancer	0.000392	0.00131	CcSEcCtD
Cyclophosphamide—Anorexia—Sorafenib—liver cancer	0.00039	0.0013	CcSEcCtD
Cyclophosphamide—Hyperkalaemia—Doxorubicin—liver cancer	0.000386	0.00128	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Epirubicin—liver cancer	0.000383	0.00128	CcSEcCtD
Cyclophosphamide—Bladder pain—Epirubicin—liver cancer	0.000383	0.00128	CcSEcCtD
Cyclophosphamide—Neoplasm—Epirubicin—liver cancer	0.000383	0.00128	CcSEcCtD
Cyclophosphamide—Cystitis noninfective—Doxorubicin—liver cancer	0.000383	0.00128	CcSEcCtD
Cyclophosphamide—Influenza like illness—Doxorubicin—liver cancer	0.000381	0.00127	CcSEcCtD
Cyclophosphamide—Cystitis—Doxorubicin—liver cancer	0.000379	0.00126	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Epirubicin—liver cancer	0.000377	0.00126	CcSEcCtD
Cyclophosphamide—Colitis—Doxorubicin—liver cancer	0.000377	0.00126	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000373	0.00124	CcSEcCtD
Cyclophosphamide—Fluid retention—Doxorubicin—liver cancer	0.000373	0.00124	CcSEcCtD
Cyclophosphamide—Sepsis—Epirubicin—liver cancer	0.000368	0.00123	CcSEcCtD
Cyclophosphamide—Dyspnoea—Sorafenib—liver cancer	0.000365	0.00122	CcSEcCtD
Cyclophosphamide—Phlebitis—Epirubicin—liver cancer	0.000357	0.00119	CcSEcCtD
Cyclophosphamide—Decreased appetite—Sorafenib—liver cancer	0.000356	0.00119	CcSEcCtD
Cyclophosphamide—Bladder pain—Doxorubicin—liver cancer	0.000355	0.00118	CcSEcCtD
Cyclophosphamide—Neoplasm—Doxorubicin—liver cancer	0.000355	0.00118	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Doxorubicin—liver cancer	0.000355	0.00118	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Epirubicin—liver cancer	0.000354	0.00118	CcSEcCtD
Cyclophosphamide—Fatigue—Sorafenib—liver cancer	0.000353	0.00118	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Epirubicin—liver cancer	0.000352	0.00117	CcSEcCtD
Cyclophosphamide—Constipation—Sorafenib—liver cancer	0.00035	0.00117	CcSEcCtD
Cyclophosphamide—Pain—Sorafenib—liver cancer	0.00035	0.00117	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Doxorubicin—liver cancer	0.000349	0.00116	CcSEcCtD
Cyclophosphamide—Hepatic failure—Epirubicin—liver cancer	0.000343	0.00114	CcSEcCtD
Cyclophosphamide—Sepsis—Doxorubicin—liver cancer	0.000341	0.00113	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Epirubicin—liver cancer	0.000339	0.00113	CcSEcCtD
Cyclophosphamide—Renal failure acute—Epirubicin—liver cancer	0.000333	0.00111	CcSEcCtD
Cyclophosphamide—Phlebitis—Doxorubicin—liver cancer	0.000331	0.0011	CcSEcCtD
Cyclophosphamide—Hot flush—Epirubicin—liver cancer	0.000329	0.0011	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Doxorubicin—liver cancer	0.000327	0.00109	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Epirubicin—liver cancer	0.000326	0.00109	CcSEcCtD
Cyclophosphamide—Hepatic function abnormal—Doxorubicin—liver cancer	0.000326	0.00109	CcSEcCtD
Cyclophosphamide—Urticaria—Sorafenib—liver cancer	0.000325	0.00108	CcSEcCtD
Cyclophosphamide—Body temperature increased—Sorafenib—liver cancer	0.000324	0.00108	CcSEcCtD
Cyclophosphamide—Renal impairment—Epirubicin—liver cancer	0.000323	0.00108	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Epirubicin—liver cancer	0.000322	0.00107	CcSEcCtD
Cyclophosphamide—Hepatic failure—Doxorubicin—liver cancer	0.000317	0.00106	CcSEcCtD
Cyclophosphamide—Cardiac failure—Epirubicin—liver cancer	0.000315	0.00105	CcSEcCtD
Cyclophosphamide—Cardiac failure congestive—Doxorubicin—liver cancer	0.000314	0.00105	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Epirubicin—liver cancer	0.000309	0.00103	CcSEcCtD
Cyclophosphamide—Renal failure acute—Doxorubicin—liver cancer	0.000309	0.00103	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000308	0.00103	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—liver cancer	0.000305	0.00101	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—liver cancer	0.000302	0.00101	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Sorafenib—liver cancer	0.000302	0.001	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—liver cancer	0.000299	0.000997	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—liver cancer	0.000298	0.000993	CcSEcCtD
Cyclophosphamide—Asthenia—Sorafenib—liver cancer	0.000294	0.000979	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Epirubicin—liver cancer	0.000293	0.000975	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—liver cancer	0.000292	0.000972	CcSEcCtD
Cyclophosphamide—Pruritus—Sorafenib—liver cancer	0.00029	0.000965	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—liver cancer	0.000286	0.000953	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000285	0.000949	CcSEcCtD
Cyclophosphamide—Diarrhoea—Sorafenib—liver cancer	0.00028	0.000933	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000277	0.000924	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—liver cancer	0.000275	0.000917	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—liver cancer	0.000271	0.000902	CcSEcCtD
Cyclophosphamide—Dizziness—Sorafenib—liver cancer	0.000271	0.000902	CcSEcCtD
Cyclophosphamide—Vomiting—Sorafenib—liver cancer	0.00026	0.000867	CcSEcCtD
Cyclophosphamide—Rash—Sorafenib—liver cancer	0.000258	0.00086	CcSEcCtD
Cyclophosphamide—Dermatitis—Sorafenib—liver cancer	0.000258	0.000859	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000257	0.000855	CcSEcCtD
Cyclophosphamide—Headache—Sorafenib—liver cancer	0.000256	0.000854	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—liver cancer	0.000255	0.000849	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—liver cancer	0.000253	0.000842	CcSEcCtD
Cyclophosphamide—Nausea—Sorafenib—liver cancer	0.000243	0.00081	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—liver cancer	0.000242	0.000807	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—liver cancer	0.00024	0.0008	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—liver cancer	0.000239	0.000795	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000235	0.000784	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—liver cancer	0.000234	0.000779	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—liver cancer	0.000233	0.000777	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—liver cancer	0.000233	0.000775	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—liver cancer	0.000231	0.00077	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—liver cancer	0.000231	0.00077	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—liver cancer	0.000231	0.000768	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—liver cancer	0.000227	0.000758	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—liver cancer	0.000226	0.000754	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—liver cancer	0.000224	0.000746	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—liver cancer	0.000222	0.00074	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—liver cancer	0.000221	0.000738	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—liver cancer	0.000221	0.000736	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000218	0.000725	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—liver cancer	0.000217	0.000722	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—liver cancer	0.000216	0.000719	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000215	0.000717	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—liver cancer	0.000214	0.000713	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—liver cancer	0.000214	0.000713	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—liver cancer	0.000214	0.000713	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—liver cancer	0.000214	0.000711	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—liver cancer	0.000213	0.000711	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—liver cancer	0.000213	0.00071	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—liver cancer	0.000213	0.00071	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—liver cancer	0.000212	0.000706	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—liver cancer	0.00021	0.000701	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—liver cancer	0.000209	0.000697	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—liver cancer	0.000205	0.000684	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—liver cancer	0.000205	0.000682	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—liver cancer	0.000201	0.000671	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—liver cancer	0.000201	0.000668	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—liver cancer	0.000199	0.000662	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—liver cancer	0.000198	0.00066	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—liver cancer	0.000198	0.000658	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—liver cancer	0.000198	0.000658	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—liver cancer	0.000197	0.000657	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—liver cancer	0.000197	0.000657	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—liver cancer	0.000196	0.000653	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—liver cancer	0.000191	0.000637	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—liver cancer	0.00019	0.000634	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—liver cancer	0.00019	0.000633	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—liver cancer	0.000188	0.000627	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—liver cancer	0.000186	0.000621	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—liver cancer	0.000185	0.000618	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—liver cancer	0.000184	0.000612	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—liver cancer	0.000183	0.000609	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—liver cancer	0.000182	0.000605	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—liver cancer	0.000178	0.000594	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—liver cancer	0.000177	0.000589	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—liver cancer	0.000176	0.000586	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—liver cancer	0.000175	0.000582	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—liver cancer	0.000174	0.00058	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—liver cancer	0.000172	0.000573	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—liver cancer	0.000172	0.000571	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—liver cancer	0.000171	0.000571	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—liver cancer	0.00017	0.000568	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—liver cancer	0.000168	0.00056	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—liver cancer	0.000167	0.000557	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—liver cancer	0.000166	0.000553	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—liver cancer	0.000165	0.000549	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—liver cancer	0.000164	0.000546	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—liver cancer	0.000162	0.000539	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—liver cancer	0.000162	0.000539	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—liver cancer	0.000161	0.000535	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—liver cancer	0.00016	0.000533	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—liver cancer	0.000159	0.00053	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—liver cancer	0.000159	0.000528	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—liver cancer	0.000158	0.000526	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—liver cancer	0.000158	0.000526	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—liver cancer	0.000158	0.000526	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—liver cancer	0.000158	0.000525	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—liver cancer	0.000156	0.00052	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—liver cancer	0.000155	0.000515	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—liver cancer	0.000154	0.000512	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—liver cancer	0.000153	0.000508	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—liver cancer	0.000152	0.000505	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—liver cancer	0.000151	0.000504	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—liver cancer	0.000151	0.000504	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—liver cancer	0.00015	0.000501	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—liver cancer	0.00015	0.000499	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—liver cancer	0.000149	0.000496	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—liver cancer	0.000149	0.000495	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—liver cancer	0.000148	0.000494	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—liver cancer	0.000148	0.000493	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—liver cancer	0.000148	0.000492	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—liver cancer	0.000146	0.000487	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—liver cancer	0.000146	0.000487	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—liver cancer	0.000146	0.000487	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—liver cancer	0.000146	0.000487	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—liver cancer	0.000144	0.000481	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—liver cancer	0.000144	0.000481	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—liver cancer	0.000141	0.000471	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—liver cancer	0.000141	0.00047	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—liver cancer	0.00014	0.000466	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—liver cancer	0.00014	0.000466	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—liver cancer	0.000139	0.000463	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000138	0.000459	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—liver cancer	0.000138	0.000459	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—liver cancer	0.000137	0.000457	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—liver cancer	0.000137	0.000455	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—liver cancer	0.000136	0.000453	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—liver cancer	0.000135	0.000451	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—liver cancer	0.000135	0.000449	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—liver cancer	0.000133	0.000445	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—liver cancer	0.000132	0.000438	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—liver cancer	0.000131	0.000436	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—liver cancer	0.00013	0.000435	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—liver cancer	0.000129	0.000431	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—liver cancer	0.000129	0.000431	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000128	0.000425	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—liver cancer	0.000126	0.000419	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—liver cancer	0.000125	0.000416	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—liver cancer	0.000125	0.000415	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—liver cancer	0.000122	0.000405	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—liver cancer	0.000121	0.000402	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—liver cancer	0.00012	0.0004	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—liver cancer	0.00012	0.000399	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—liver cancer	0.00012	0.000399	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—liver cancer	0.00012	0.000398	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—liver cancer	0.000115	0.000384	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—liver cancer	0.000111	0.000371	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—liver cancer	0.000111	0.000371	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—liver cancer	0.000111	0.000369	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—liver cancer	0.000109	0.000362	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—liver cancer	0.000107	0.000357	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—liver cancer	0.000104	0.000345	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—liver cancer	0.000103	0.000344	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—liver cancer	0.0001	0.000335	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—liver cancer	0.0001	0.000333	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—liver cancer	9.91e-05	0.00033	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—liver cancer	9.62e-05	0.000321	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—liver cancer	9.58e-05	0.000319	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—liver cancer	9.54e-05	0.000318	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—liver cancer	9.53e-05	0.000318	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—liver cancer	9.48e-05	0.000316	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—liver cancer	9.26e-05	0.000308	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—liver cancer	8.99e-05	0.000299	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—liver cancer	8.9e-05	0.000297	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—liver cancer	8.83e-05	0.000294	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—liver cancer	8.82e-05	0.000294	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—liver cancer	8.77e-05	0.000292	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—liver cancer	8.32e-05	0.000277	CcSEcCtD
Cyclophosphamide—ABCB1—Metabolism—NAT2—liver cancer	2e-05	0.000161	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTA2—liver cancer	1.97e-05	0.000159	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTP1—liver cancer	1.97e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.97e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ALDOB—liver cancer	1.96e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.96e-05	0.000158	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTA2—liver cancer	1.95e-05	0.000157	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PPARG—liver cancer	1.95e-05	0.000157	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—HMOX1—liver cancer	1.94e-05	0.000156	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PSMA4—liver cancer	1.93e-05	0.000155	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PSMD10—liver cancer	1.93e-05	0.000155	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ALDOB—liver cancer	1.91e-05	0.000154	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTA1—liver cancer	1.9e-05	0.000153	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.89e-05	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTA1—liver cancer	1.89e-05	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PSMA4—liver cancer	1.88e-05	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PSMD10—liver cancer	1.88e-05	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—NAT2—liver cancer	1.88e-05	0.000151	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GOT2—liver cancer	1.88e-05	0.000151	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CRABP1—liver cancer	1.87e-05	0.000151	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—NAT2—liver cancer	1.86e-05	0.00015	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.84e-05	0.000148	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GOT2—liver cancer	1.83e-05	0.000148	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—HPGDS—liver cancer	1.83e-05	0.000147	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CRABP1—liver cancer	1.83e-05	0.000147	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	1.83e-05	0.000147	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.82e-05	0.000147	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GSTM1—liver cancer	1.81e-05	0.000145	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALDOB—liver cancer	1.8e-05	0.000145	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTP1—liver cancer	1.8e-05	0.000145	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.79e-05	0.000144	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALDOB—liver cancer	1.79e-05	0.000144	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.78e-05	0.000143	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—HMOX1—liver cancer	1.78e-05	0.000143	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CD—liver cancer	1.77e-05	0.000143	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP2E1—liver cancer	1.76e-05	0.000142	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—ALB—liver cancer	1.75e-05	0.000141	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP2E1—liver cancer	1.72e-05	0.000139	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CRABP1—liver cancer	1.72e-05	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP1A1—liver cancer	1.71e-05	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CRABP1—liver cancer	1.71e-05	0.000137	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.68e-05	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.66e-05	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GSTM1—liver cancer	1.66e-05	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYCS—liver cancer	1.65e-05	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.64e-05	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—HPGDS—liver cancer	1.64e-05	0.000132	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PSMA4—liver cancer	1.63e-05	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PSMD10—liver cancer	1.63e-05	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.63e-05	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GGT1—liver cancer	1.62e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GOT1—liver cancer	1.62e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYCS—liver cancer	1.61e-05	0.00013	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—MTHFR—liver cancer	1.6e-05	0.000129	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—HPGDS—liver cancer	1.6e-05	0.000128	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GOT2—liver cancer	1.59e-05	0.000128	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GGT1—liver cancer	1.58e-05	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GOT1—liver cancer	1.58e-05	0.000127	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP1A1—liver cancer	1.57e-05	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PPARA—liver cancer	1.57e-05	0.000126	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CB—liver cancer	1.55e-05	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.54e-05	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CPT1B—liver cancer	1.53e-05	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GLUL—liver cancer	1.53e-05	0.000123	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—HPGDS—liver cancer	1.5e-05	0.000121	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.5e-05	0.000121	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP2E1—liver cancer	1.49e-05	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—HPGDS—liver cancer	1.49e-05	0.00012	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.48e-05	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.48e-05	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NR1H4—liver cancer	1.47e-05	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—MTHFR—liver cancer	1.46e-05	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.46e-05	0.000118	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PSMA4—liver cancer	1.46e-05	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PSMD10—liver cancer	1.46e-05	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTP1—liver cancer	1.45e-05	0.000117	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTA3—liver cancer	1.45e-05	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.45e-05	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PPARA—liver cancer	1.44e-05	0.000116	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—HMOX1—liver cancer	1.43e-05	0.000115	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PSMA4—liver cancer	1.42e-05	0.000114	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PSMD10—liver cancer	1.42e-05	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTP1—liver cancer	1.42e-05	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GOT2—liver cancer	1.42e-05	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—HMOX1—liver cancer	1.4e-05	0.000113	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYCS—liver cancer	1.4e-05	0.000112	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GOT2—liver cancer	1.38e-05	0.000111	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GGT1—liver cancer	1.37e-05	0.00011	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GOT1—liver cancer	1.37e-05	0.00011	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.36e-05	0.000109	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.35e-05	0.000109	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CG—liver cancer	1.34e-05	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PSMA4—liver cancer	1.34e-05	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PSMD10—liver cancer	1.34e-05	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GSTM1—liver cancer	1.34e-05	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP2E1—liver cancer	1.33e-05	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.33e-05	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PSMA4—liver cancer	1.33e-05	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PSMD10—liver cancer	1.33e-05	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTA4—liver cancer	1.32e-05	0.000106	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GSTM1—liver cancer	1.31e-05	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GOT2—liver cancer	1.3e-05	0.000105	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP2E1—liver cancer	1.3e-05	0.000105	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PPARG—liver cancer	1.3e-05	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GOT2—liver cancer	1.29e-05	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.29e-05	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTA2—liver cancer	1.29e-05	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP1A1—liver cancer	1.27e-05	0.000102	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYCS—liver cancer	1.25e-05	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTA1—liver cancer	1.24e-05	0.0001	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP1A1—liver cancer	1.24e-05	9.97e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTP1—liver cancer	1.23e-05	9.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CG—liver cancer	1.23e-05	9.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—NAT2—liver cancer	1.23e-05	9.9e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.23e-05	9.87e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP2E1—liver cancer	1.23e-05	9.87e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GGT1—liver cancer	1.22e-05	9.85e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GOT1—liver cancer	1.22e-05	9.85e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYCS—liver cancer	1.22e-05	9.8e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP2E1—liver cancer	1.22e-05	9.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—HMOX1—liver cancer	1.21e-05	9.77e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GGT1—liver cancer	1.19e-05	9.61e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GOT1—liver cancer	1.19e-05	9.61e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PPARG—liver cancer	1.19e-05	9.56e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—MTHFR—liver cancer	1.18e-05	9.51e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CD—liver cancer	1.18e-05	9.5e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALDOB—liver cancer	1.18e-05	9.49e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.18e-05	9.47e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ALB—liver cancer	1.16e-05	9.37e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PPARA—liver cancer	1.16e-05	9.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—MTHFR—liver cancer	1.15e-05	9.29e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYCS—liver cancer	1.15e-05	9.23e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYCS—liver cancer	1.14e-05	9.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PPARA—liver cancer	1.13e-05	9.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GSTM1—liver cancer	1.13e-05	9.11e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GOT1—liver cancer	1.13e-05	9.06e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GGT1—liver cancer	1.13e-05	9.06e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CRABP1—liver cancer	1.12e-05	9.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GGT1—liver cancer	1.12e-05	8.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GOT1—liver cancer	1.12e-05	8.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTP1—liver cancer	1.1e-05	8.85e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—HMOX1—liver cancer	1.08e-05	8.72e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CD—liver cancer	1.08e-05	8.7e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTP1—liver cancer	1.07e-05	8.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP1A1—liver cancer	1.07e-05	8.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ALB—liver cancer	1.07e-05	8.59e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—HMOX1—liver cancer	1.06e-05	8.52e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CB—liver cancer	1.03e-05	8.28e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTP1—liver cancer	1.01e-05	8.14e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GSTM1—liver cancer	1.01e-05	8.13e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTP1—liver cancer	1e-05	8.07e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—MTHFR—liver cancer	1e-05	8.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—HMOX1—liver cancer	9.97e-06	8.02e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CG—liver cancer	9.93e-06	7.99e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—HMOX1—liver cancer	9.88e-06	7.96e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GSTM1—liver cancer	9.86e-06	7.93e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—HPGDS—liver cancer	9.83e-06	7.91e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PPARA—liver cancer	9.81e-06	7.9e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CG—liver cancer	9.7e-06	7.81e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PPARG—liver cancer	9.58e-06	7.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP1A1—liver cancer	9.58e-06	7.71e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—PIK3CA—liver cancer	9.43e-06	7.59e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CB—liver cancer	9.43e-06	7.59e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PPARG—liver cancer	9.36e-06	7.54e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP1A1—liver cancer	9.35e-06	7.52e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GSTM1—liver cancer	9.29e-06	7.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GSTM1—liver cancer	9.21e-06	7.41e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—MTHFR—liver cancer	8.93e-06	7.18e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.81e-06	7.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP1A1—liver cancer	8.81e-06	7.09e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PSMA4—liver cancer	8.76e-06	7.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PSMD10—liver cancer	8.76e-06	7.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PPARA—liver cancer	8.76e-06	7.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP1A1—liver cancer	8.73e-06	7.03e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CD—liver cancer	8.73e-06	7.02e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—MTHFR—liver cancer	8.71e-06	7.01e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ALB—liver cancer	8.61e-06	6.93e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PPARA—liver cancer	8.55e-06	6.88e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CD—liver cancer	8.53e-06	6.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GOT2—liver cancer	8.52e-06	6.86e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ALB—liver cancer	8.42e-06	6.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CG—liver cancer	8.4e-06	6.76e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—MTHFR—liver cancer	8.21e-06	6.61e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—MTHFR—liver cancer	8.14e-06	6.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PPARG—liver cancer	8.11e-06	6.53e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PPARA—liver cancer	8.06e-06	6.48e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP2E1—liver cancer	8.02e-06	6.45e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PPARA—liver cancer	7.99e-06	6.43e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.87e-06	6.33e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—AKT1—liver cancer	7.7e-06	6.2e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CB—liver cancer	7.61e-06	6.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CG—liver cancer	7.5e-06	6.04e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYCS—liver cancer	7.5e-06	6.04e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CB—liver cancer	7.43e-06	5.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CD—liver cancer	7.39e-06	5.95e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GOT1—liver cancer	7.36e-06	5.92e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GGT1—liver cancer	7.36e-06	5.92e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CG—liver cancer	7.32e-06	5.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ALB—liver cancer	7.29e-06	5.87e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PPARG—liver cancer	7.24e-06	5.83e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.17e-06	5.77e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PPARG—liver cancer	7.07e-06	5.69e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CG—liver cancer	6.9e-06	5.55e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CG—liver cancer	6.84e-06	5.5e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PPARG—liver cancer	6.66e-06	5.36e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTP1—liver cancer	6.61e-06	5.32e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PPARG—liver cancer	6.6e-06	5.31e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CD—liver cancer	6.59e-06	5.31e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—HMOX1—liver cancer	6.52e-06	5.25e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ALB—liver cancer	6.51e-06	5.24e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CB—liver cancer	6.44e-06	5.18e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CD—liver cancer	6.44e-06	5.18e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ALB—liver cancer	6.35e-06	5.11e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—PIK3CA—liver cancer	6.27e-06	5.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GSTM1—liver cancer	6.07e-06	4.89e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CD—liver cancer	6.06e-06	4.88e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CD—liver cancer	6.01e-06	4.84e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALB—liver cancer	5.99e-06	4.82e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALB—liver cancer	5.94e-06	4.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP1A1—liver cancer	5.76e-06	4.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CB—liver cancer	5.75e-06	4.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—PIK3CA—liver cancer	5.75e-06	4.62e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CB—liver cancer	5.61e-06	4.51e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—MTHFR—liver cancer	5.37e-06	4.32e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CB—liver cancer	5.29e-06	4.25e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PPARA—liver cancer	5.27e-06	4.24e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CB—liver cancer	5.24e-06	4.22e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—AKT1—liver cancer	5.12e-06	4.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—AKT1—liver cancer	4.69e-06	3.78e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—PIK3CA—liver cancer	4.64e-06	3.73e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—PIK3CA—liver cancer	4.53e-06	3.65e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CG—liver cancer	4.51e-06	3.63e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PPARG—liver cancer	4.35e-06	3.5e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CD—liver cancer	3.97e-06	3.19e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—PIK3CA—liver cancer	3.93e-06	3.16e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALB—liver cancer	3.91e-06	3.15e-05	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—AKT1—liver cancer	3.79e-06	3.05e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—AKT1—liver cancer	3.7e-06	2.98e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—PIK3CA—liver cancer	3.5e-06	2.82e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CB—liver cancer	3.46e-06	2.78e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—PIK3CA—liver cancer	3.42e-06	2.75e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—PIK3CA—liver cancer	3.22e-06	2.59e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—AKT1—liver cancer	3.21e-06	2.58e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—PIK3CA—liver cancer	3.19e-06	2.57e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—AKT1—liver cancer	2.86e-06	2.3e-05	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—AKT1—liver cancer	2.79e-06	2.25e-05	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—AKT1—liver cancer	2.63e-06	2.12e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—AKT1—liver cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—PIK3CA—liver cancer	2.11e-06	1.7e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—AKT1—liver cancer	1.72e-06	1.39e-05	CbGpPWpGaD
